Replies to post #5238 on Revance Therapeutics Inc (RVNC)

[vinmantoo]

None of this really matters in aesthetics. 50% of the patients will be disappointed. They will not get the duration and will be disappointed. Very few patients will continue to pay extra for a little bit better on average.

That is an incredibly foolish comment. First of all that means 50% of the patients treated will be very happy with a superior product that give longer duration effects. That means they will drop Boxox and become a regular. That sounds good to me and good for RVNC. Second, even the people who don't get 6 months duration could get 4 months or 5 months duration, both being longer than Botox. That means they will be happy and drop Botox to become regular Daxxify users. Third, any competent doctor would explain what the median means. It means that half the people using Daxxify gets 6 month duration, the rest are split between longer and shorter duration. It sounds like you think physicians are stupid enough or foolish enough to guarantee a 6 months duration. Are you and your wife in that category?

Please cut your losses in aesthetics and move to maximize therapeutic profits.

That is an incredibly foolish comment. Why in the would RVNC drop a profitable sales area instead of pushing both aesthetics and therapeutics?

[Aestheticexec]

There is now enough experience to know you can’t predict who will get the extended duration. It’s a flip of the coin. That doesn’t work for a premium product - anyone in retail will understand. It would work in therapeutics where recipients are hopeful and playing with house money. Not saying abandon, but experiment failed badly while several layers of the company missed all the warning signs. Shift investment.